 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
 This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices. Please stay on topic. Provectus Pharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. The product pipeline Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov. ----------------------------------------------------------------------------------------------------------------------------------------------- PV-10 link to video and visual references: http://www.pvct.com/multimedianews.html PV-10 Trial Participants Telling Their Own Stories in the News http://www.pvct.com/pv10-videos.html May 17, 2007 Professor Peter Hersey, M.D. comments on PV-10 and a patient's response Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response. Video can be viewed here. http://www.pvct.com/hersey_pv10_video.html?pg=2 This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live. Video can be viewed here. http://www.pvct.com/hersey_pv10_video.html?pg=5 2008, Charles Dawson, PV10 patient, Australia; Professor John Thompson, Sydney Melanoma Unit Video can be viewed here https://www.youtube.com/watch?v=HSjoev_q9Nw December 16, 2010 Madja Rauh recently traveled to Bethlehem with her daughter Ursa Rauh from Ljubljana, the capital of Slovenia in Europe, to receive a promising, experimental treatment for metastatic melanoma with internationally recognized melanoma investigator Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology, St. Luke's Hospital & Health Network,Bethlehem, PA Video can be viewed here. http://www.slhn.org/News/2010/Slovenian-Woman-Receives-Treatment http://www.pvct.com/inthenews.html?article=20110725&mode=0 Madja Rauh, PV10 patient, has a Facebook page as of 1/ 2015 http://www.pvct.com/inthenews.html?article=20070321&mode=0 http://www.pvct.com/inthenews.html?article=20110725&mode=0 Madja Rauh, PV-10 patient, has a Facebook page as of January 2015 -------------------------------------------------------------- Contact Info Our Contact Form Telephone: +1 (866) 594-5999 Fax: +1 (866) 998-0005 info@pvct.com Mailing Address: Provectus Pharmaceuticals, Inc. 7327 Oak Ridge Hwy Knoxville, TN 37931 USA • MAP Transfer Agent: (i.e. stockholder records, transfer, change of address, etc.) Broadridge Corporate Issuer Solutions, Inc. Laura Skorny 1717 Arch Street, Suite 1300 Philadelphia, PA 19103 E-mail: Laura.Skorny@Broadridge.com Telephone: +1 (610) 649-7300 Fax: +1 (610) 649-7302 Investor Relations: Porter, LeVay & Rose, Inc. Marlon A. Nurse Seven Penn Plaza New York, NY 10001 Telephone: 212-564-4700 Fax: 212-244-3075 marlon@plrinvest.com Media Relations: Porter, LeVay & Rose, Inc. Bill Gordon Seven Penn Plaza New York, NY 10001 Telephone: 212-564-4700 bill@plrinvest.com Investment Advisor: Network 1 Financial Securities Damon Testaverde Telephone: +1 (800) 205-8031 ----------------------------------------------------------- | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2024 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |